Skip to content
Review

Efficacy and Safety of Savolitinib Plus Osimertinib in EGFR-Mutant, MET-Aberrant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Sep 2026 · American Journal of Clinical Oncology · 0 citations · 31 references
Medicine

TL;DR

Combined therapy shows encouraging results in selected MET, post-TKI NSCLC, however, reliance on single-arm data warrants further randomized controlled trials.

Abstract

Objectives

NSCLC is the leading cause of cancer-related mortality. While combined therapy including savolitinib and osimertinib appears promising, there exists a lack of comprehensive pooled evidence regarding its anti-oncological activity. The objective of this study is to evaluate the efficacy and safety of combined therapy in patients with NSCLC.

Methods

A comprehensive literature search was conducted in MEDLINE, the Cochrane Central Register of controlled trials, and ClinicalTrials.gov. Randomized controlled trials and prospective single-arm studies evaluating savolitinib combined with osimertinib were included. A random-effects single-arm meta-analysis of proportions was performed using logit transformation and inverse variance weighting, with restricted maximum likelihood (REML) estimation and Knapp-Hartung adjustment. Results were reported with a 95% CI, and heterogeneity was assessed using the I2 statistic. Sensitivity analysis was conducted using the Freeman-Tukey transformation.

Results

The primary analysis included 4 post-TKI, MET-selected combination cohorts (SACHI, SAVANNAH, and TATTON Part B; n=338) from 7 reports of 5 trials after de-duplication of overlapping data sets. First-line (FLOWERS) and MET-unselected (Yoh) cohorts were analyzed separately. The pooled objective response rate (ORR) was 53.9% (95% CI: 45.1-62.4), disease control rate (DCR) was 85.2% (79.2-89.8), 6-month progression-free survival (PFS) rate was 59.8%, and grade ≥3 adverse events occurred in 48.8% of patients. ORR estimates were consistent across studies and remained robust across sensitivity and subgroup analyses.

Conclusions

Combined therapy shows encouraging results in selected MET, post-TKI NSCLC. However, reliance on single-arm data warrants further randomized controlled trials.

View source

Similar papers

Review Sep 2026

Efficacy of Veliparib Plus Temozolomide Combination Therapy in Cancer: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Clinical Trials.

This meta-analysis did not demonstrate a statistically significant OS and PFS benefit from veliparib plus temozolomide compared with control therapy, and future studies should focus on biomarker-driven approaches and optimized dosing strategies to better define the clinical utility of this regimen.

Parsa Sepehri, F. Hejazi, Milad Ghanikolahloo et al. · 0 citations
Review Sep 2026

Clinical Outcomes of Sacituzumab Govitecan in Breast Cancer: A Systematic Review, Meta-Analysis, and GRADE Assessment of Randomized Evidence.

OBJECTIVES Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate delivering SN-38, has shown promising activity in advanced breast cancer. However, variability across trials and inclusion of nonrandomized data in prior meta-analyses limit the certainty of its efficacy and safety. This study aimed to eva...

M. Amjad, M. Rafique, S. F. Hussain et al. · 0 citations
Review Open access Oct 2026

Comparative effectiveness and safety of almonertinib in EGFR-mutated non-small cell lung cancer: an integrated evidence synthesis

Background Comparative evidence regarding the efficacy and safety of almonertinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) remains fragmented across randomized and real-world studies. We conducted a systematic review and meta-analysis to comprehensively evaluate the comparat...

Biao-Xue Rong, Hui Pan, T. Fu et al. · 0 citations
Review Open access Oct 2026

Comparative efficacy of fruquintinib, regorafenib or TAS-102 in patients with KRAS-mutant metastatic colorectal cancer: a systematic review and network meta-analysis

Objective This study aimed to synthesize evidence from recent randomized controlled trials (RCTs) evaluating the efficacy of regorafenib, fruquintinib, and TAS-102 in patients with metastatic colorectal cancer (mCRC). Using a network meta-analysis, we compared long-term survival outcomes (overall and progression-free s...

Ying-Yu Zhou, Shi-Qing Zhao, Xiao-Yi Zheng et al. · 0 citations
Review Oct 2026

Enzalutamide alone or combined with other pharmacologic agents for metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.

BackgroundMetastatic castration-resistant prostate cancer (mCRPC) remains driven by persistent androgen receptor signaling. Although enzalutamide (ENZ) is widely used, the incremental benefit of adding other agents remains uncertain. We evaluated the efficacy and safety of specific pharmacologic agents added to ENZ in...

Yeison Cruz Castillo, Alejandro Chen Liang, Victor M. Samperio et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.